Active pharmaceutical ingredients are delivered through pathogen cell walls using Phillips’ drug delivery technology. When the active pharmaceutical ingredients are combined with tetracycline, the resulting product is a
The instrument makes use of a software and E-Plates 96 to measure electronic cell impedance using sensor electrodes. Continual detection of changes in cell behavior using 96-well culture
In the trial, around 600 patients are expected to be enrolled who have failed prior systemic therapy. Further, the patients will be given weekly intramuscular injections of ADI-PEG
Peginesatide, a synthetic, PEGylated peptidic compound, is a erythropoiesis stimulating agent (ESA) that binds and activates the erythropoietin receptor. The NDA submission is based on data from two
Additionally, NIH has selected Viamet’s novel antifungal compounds for inclusion in the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program. Viamet president and
Cogane is an orally bioavailable neurotrophic factor inducer that crosses the blood-brain barrier and shows neuroprotective effects. The interim results of Cogane show promising activity in preclinical in
Febuxostat, a non-purine selective inhibitor of xanthine oxidase is used to treat chronic hyperuricemia in gout patients. Teijin Pharma signed a licensing agreement with SK Chemicals in July
SEBVI Technology uses Epstein Barr Virus for immortalizing and isolating circulating human B cells from the blood of immunocompetent individuals which secrete antigen-specific IgG antibodies. PX’T plans to
The Phase 3 trial which aims at over all survival, is a double-blind, randomized trial involved around 430 patients to compare the safety and efficacy of perifosine +
Currently, mipomersen is in late-stage development for the reduction of LDL cholesterol (LDL-C). Genzyme and Isis Pharma said that if approved the drug will be marketed under Kynamro
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.